Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
netFormulary
Home
Treatment Use
Class
Chapters
News
Reports
Contact
SEARCH
Searching for :
Ibrutinib
Open monograph to display formulary status.
Formulary items found
Status
Description
Section
RED
Ibrutinib 140mg Imbruvica
®
(Capsules)
Malignant disease and immunosuppression, Other antineoplastic drugs, 08.01.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local
BNF
Section
Ibrutinib
Ibrutinib [Specialist Drug]
Malignant Disease, Antineoplastic Drugs, Protein Kinase Inhibitors
Targeted Therapy Responsive Malignancy
Links found
MHRA DSU Aug 17: Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
NICE TA429: Ibrutinib for previously treated CLL
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
NICE TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia